Vivo Capital IX, LLC - 23 Jun 2021 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
10%+ Owner
Signature
/s/Frank Kung, Managing Member of Vivo Capital IX, LLC
Issuer symbol
TARS
Transactions as of
23 Jun 2021
Net transactions value
-$1,658,842
Form type
4
Filing time
25 Jun 2021, 21:30:34 UTC
Previous filing
25 Jun 2021
Next filing
04 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Sale $1,131,804 -37,980 -1.2% $29.80 3,005,035 23 Jun 2021 See Footnote F1, F4
transaction TARS Common Stock Sale $299,000 -10,000 -0.33% $29.90 2,995,035 24 Jun 2021 See Footnote F2, F4
transaction TARS Common Stock Sale $228,038 -7,704 -0.26% $29.60 2,987,331 25 Jun 2021 See Footnote F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.6 to $28.3, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2 The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2 to $29.7, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.0 to $29.5, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.